Xenetic Biosciences, Inc. (XBIO) stock
XBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 12/3064% below fair value
$1.61+0.12 (+8.05%)
Close on Nov 17, 2026Market cap $3.77MP/E –Yield –
Xenetic Biosciences price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Xenetic Biosciences's price to sales ratio was 1.3× on Nov 11, 2026, against 1.4× a year earlier. Over the last 5 years it ranged from 1.2× to 17.6×, with a median of 2.6×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 1.3× | +0.2 |
| 2025 | Dec 31, 2025 | 1.2× | −1.3 |
| 2024 | Dec 31, 2024 | 2.4× | −0.7 |
| 2023 | Dec 29, 2023 | 3.1× | +0.4 |
| 2022 | Dec 30, 2022 | 2.7× | −14.9 |
| 2021 | Dec 31, 2021 | 17.6× | −24.8 |
| 2020 | Dec 31, 2020 | 42.4× | +40.4 |
| 2018 | Apr 30, 2018 | 2.1× | −5.1 |
| 2017 | Apr 28, 2017 | 7.2× | – |
See a number that looks wrong?